Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Get Free Report) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 16,000 shares, a decrease of 49.4% from the June 30th total of 31,600 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily volume of 49,400 shares, the short-interest ratio is presently 0.3 days.
Sonnet BioTherapeutics Stock Performance
NASDAQ:SONN traded up $0.01 during trading hours on Friday, reaching $0.86. The company had a trading volume of 40,221 shares, compared to its average volume of 74,326. The stock has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.57. Sonnet BioTherapeutics has a one year low of $0.82 and a one year high of $10.09.
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported $0.07 earnings per share for the quarter. Sonnet BioTherapeutics had a negative net margin of 11,187.19% and a negative return on equity of 382.31%. As a group, analysts predict that Sonnet BioTherapeutics will post -2.14 EPS for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Analysis on Sonnet BioTherapeutics
About Sonnet BioTherapeutics
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Read More
- Five stocks we like better than Sonnet BioTherapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Use the MarketBeat Stock Screener
- Why Call Options Volume for These 2 Stocks Spiked Together
- How is Compound Interest Calculated?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.